July 20 (SeeNews) - Switzerland-based generic pharmaceuticals producer Sandoz, a unit of Novartis, plans to invest $90 million (80 million euro) in the establishment of a dedicated Sandoz Biopharma Development Center at its site in Slovenia's capital Ljubljana, it said on Thursday.